Search results
Results from the WOW.Com Content Network
In 2021, Demasi co-authored a paper with Robert DuBroff challenging statin therapy. [16] As of 2022, Demasi is a writer for the Brownstone Institute, an organization that has been criticized by medical experts for spreading misinformation against vaccines. [17] [18]
New research finds that many people currently taking statins to lower cholesterol may not actually need this medication. An analysis, published in JAMA Internal Medicine , investigates how statin ...
The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP). JUPITER was the first clinical trial to indicate that statin therapy may provide benefit to patients with low-to-normal LDL levels and no known cardiovascular disease.
Statin Image Brand name Derivation Metabolism [62] Half-life Atorvastatin: Arkas, Ator, Atoris, Lipitor, Torvast, Totalip: Synthetic: CYP3A4: 14–19 hours. [164] Cerivastatin: Baycol, Lipobay (withdrawn from the market in August 2001 due to risk of serious rhabdomyolysis) Synthetic: various CYP3A isoforms [165] Fluvastatin: Lescol, Lescol XL ...
An avid runner, she is thrilled to be pain free, but she is stymied about how to manage her cholesterol. “I feel better than I have in 30 years, but my cholesterol numbers are going up,” Kim said.
Statins can be used in combination with lifestyle changes to help keep cholesterol in a healthy range. For example, people may minimize their saturated fat intake and increase their physical ...
The lipid hypothesis (also known as the cholesterol hypothesis) is a medical theory postulating a link between blood cholesterol levels and the occurrence of cardiovascular disease. A summary from 1976 described it as: "measures used to lower the plasma lipids in patients with hyperlipidemia will lead to reductions in new events of coronary ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.